Pharmacogenomic Data
Buy and sell pharmacogenomic data data. Drug metabolism genes, dosing variants, CYP profiles — pharmacogenomic AI needs genotype-to-drug-response linkage.
No listings currently in the marketplace for Pharmacogenomic Data.
Find Me This Data →Overview
What Is Pharmacogenomic Data?
Pharmacogenomic data encompasses genetic information used to predict how individuals metabolize drugs and respond to specific medications. This includes drug metabolism genes, dosing variants, and CYP enzyme profiles that link genotype to therapeutic outcomes. The field combines genomic sequencing, molecular diagnostics, and personalized medicine approaches to enable clinicians and researchers to optimize drug selection and dosing for individual patients, reducing adverse effects and improving treatment efficacy across diseases including oncology, cardiovascular conditions, and infectious diseases.
Market Data
USD 6.6 billion
Global Pharmacogenomics Market Size (2024)
Source: Global Market Insights
USD 17.7 billion
Projected Market Size (2034)
Source: Global Market Insights
10.4%
Market CAGR (2025–2034)
Source: Global Market Insights
USD 748.5 million
Molecular Diagnostics in PGx Market (2025)
Source: Future Market Insights
12.5%
Pharmacogenomics Services Market CAGR (2025–2032)
Source: Future Market Report
Who Uses This Data
What AI models do with it.do with it.
Oncology Treatment Planning
Oncology represents the fastest-growing segment in pharmacogenomics services, accounting for 42.3% of the market. Genetic profiling enables clinicians to select targeted therapies and optimize dosing for cancer patients based on tumor and germline pharmacogenomic profiles.
Cardiovascular Medication Management
Pharmacogenomic data supports personalized dosing and drug selection for cardiovascular diseases. Regulatory expansions, such as FDA-mandated pharmacogenomic labeling updates for 25 cardiovascular drugs as of May 2025, increase demand for genetic screening prior to prescription.
Precision Medicine and AI Model Development
Machine learning algorithms and AI platforms analyze large-scale pharmacogenomic datasets to enhance drug response prediction accuracy and enable computational pattern recognition for personalized therapeutic recommendations.
Diagnostic and Research Laboratories
Hospitals, clinics, diagnostic laboratories, research institutions, and academic institutes utilize pharmacogenomic data to implement genetic testing services and conduct genomic research to improve patient outcomes.
What Can You Earn?
What it's worth.worth.
Oncology-Focused Datasets
Varies
Oncology segment represents 42.3% of pharmacogenomics services market share, suggesting premium valuation for curated cancer-related pharmacogenomic datasets.
Molecular Diagnostic Datasets
Varies
Molecular diagnostics in pharmacogenomics market growing from USD 748.5 million (2025) to USD 1,450.5 million (2035) indicates strong buyer demand for sequencing and diagnostic data.
Regional/Population-Specific Data
Varies
North America leads with 38.7% market share and United States with 25.4%, indicating higher valuation for North American and US-specific pharmacogenomic datasets.
What Buyers Expect
What makes it valuable.valuable.
Drug-Gene Interaction Linkage
Data must clearly establish connections between specific genotypes and documented drug responses, dosing recommendations, and metabolic pathways. Accuracy in CYP enzyme profiling and variant annotation is critical for clinical decision-making.
Regulatory Compliance and Ethical Standards
Datasets must comply with GDPR genomic data protections, FDA pharmacogenomic labeling requirements, and ethical guidelines for informed consent, genetic data handling, storage, and further use. Compliance protocols must address evolving regulations like the EU's February 2025 GDPR amendments for genomic data.
Clinical Validation and Interpretation Standards
Data should align with established clinical guidelines and support standardized test interpretation. Buyers require well-documented variant classifications, phenotype predictions, and evidence-based therapeutic recommendations to reduce clinician uncertainty and support implementation in routine practice.
Data Privacy and Security
Robust protections against genetic discrimination and data breach are essential. Datasets must include de-identification measures and transparent data governance to build patient and provider trust and address hesitancy in adoption.
Companies Active Here
Who's buying.buying.
Leading sequencing technology provider enabling large-scale pharmacogenomic data generation and analysis for drug metabolism profiling.
Offers pharmacogenomic testing and interpretation services; active buyer of genetic variant data and drug-response datasets.
Major diagnostic laboratory and end-user acquiring pharmacogenomic datasets for clinical testing and precision medicine initiatives.
Provides sequencing instruments, molecular diagnostic tools, and platforms for processing large-scale pharmacogenomic datasets.
Supplies molecular diagnostics solutions and bioinformatics platforms for pharmacogenomic data analysis and test implementation.
FAQ
Common questions.questions.
What is driving growth in the pharmacogenomics data market?
Growth is driven by increasing demand for precision medicine, advancements in genomic sequencing technologies, rising adoption of personalized treatment approaches, regulatory mandates (such as FDA pharmacogenomic labeling requirements for medications), and investments in genomics research. The molecular diagnostics segment in pharmacogenomics is projected to grow 93.8% from 2025 to 2035, reflecting strong market momentum.
Which disease areas have the highest demand for pharmacogenomic data?
Oncology leads as the fastest-growing segment, representing 42.3% of the pharmacogenomics services market. Cardiovascular diseases, infectious diseases, neurological diseases, and pain management are also significant application areas. Regulatory expansions, including FDA-mandated genetic screening for 25 cardiovascular drugs, are expanding opportunities across multiple therapeutic areas.
What compliance and ethical standards must pharmacogenomic datasets meet?
Datasets must comply with GDPR genomic data protections (including EU amendments from February 2025), FDA pharmacogenomic labeling requirements, and ethical principles for informed consent and genetic data handling. Data must address privacy concerns, genetic discrimination risks, and include transparent governance. Documentation of variant classifications and clinical validation is essential to support clinician decision-making and build trust.
Who are the main buyers of pharmacogenomic data?
Key buyers include diagnostic laboratories (LabCorp, Quest Diagnostics), genomics companies (Illumina, Myriad Genetics, Thermo Fisher Scientific, QIAGEN), hospitals and clinics, research institutions, and academic institutes. Healthcare providers increasingly utilize pharmacogenomic data to improve patient outcomes, particularly for chronic and complex diseases. North America and the United States represent the largest markets, accounting for 38.7% and 25.4% of the pharmacogenomics services market respectively.
Sell yourpharmacogenomicdata.
If your company generates pharmacogenomic data, AI companies are actively looking for it. We handle pricing, compliance, and buyer matching.
Request Valuation